REG - Argent Biopharma Ltd - Dispatch of Annual General Meeting Documents

Argent BioPharmaAnnouncement

25/10/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241025:nRSY6578Ja&default-theme=true

RNS Number : 6578J  Argent Biopharma Limited  25 October 2024

 

25 October 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Dispatch of Annual General Meeting Documents

 

Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, would like to advise that it has
dispatched the following documentation related to its Annual General Meeting
of shareholders to be held at 4:00pm (AWST) on Thursday, 28 November 2024 at
Suite 1, 295 Rokeby Road, Subiaco Western Australia 6008, to eligible
shareholders.

 

A copy of which can be found at the following URL:

https://www.investi.com.au/api/announcements/rgt/107493c2-004.pdf
(https://www.investi.com.au/api/announcements/rgt/107493c2-004.pdf)

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.co (mailto:info@argentbiopharma.co) m   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the Central nervous system (CNS) and
Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFIFLRILLEFIS